Ibrutinib, an oral inhibitor of Bruton’s tyrosine kinase, has altered the treatment perspective of chronic lymphocytic leukemia and showed modest activity against several types of non-Hodgkin’s lymphomas. According to phase studies and real-world data, reported serious adverse effects included atrial fibrillation, diarrhea, and bleeding diathesis. However, heart failure was not reported to be a probable adverse effect linked with ibrutinib.
Case report
In this paper, we present a 66-year-old female chronic lymphocytic leukemia patient who developed significant and symptomatic left ventricular dysfunction at the 13th month of ibrutinib treatment.
Management and outcome
Following cessation of ibrutinib, ejection fraction and clinical findings of the left ventricular dysfunction alleviated.
Discussion
Although the use of ibrutinib is generally well tolerated, cardiac functions should be monitored occasionally in all patients.
ByrdJCBrownJRO'BrienS, et al.Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med2014; 371(3): 213–223.
2.
BurgerJATedeschiABarrPM, et al.Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia. N Engl J Med2015; 373(25): 2425–2437.
3.
MiklosDCutlerCSAroraM, et al.Ibrutinib for chronic graft-versus-host disease after failure of prior therapy. Blood2017; 130(21): 2243–2250.
4.
NoyAde VosSThieblemontC, et al.Targeting Bruton tyrosine kinase with ibrutinib in relapsed/refractory marginal zone lymphoma. Blood2017; 129(16): 2224–2232.
5.
DimopoulosMATedeschiATrotmanJ, et al.Phase 3 trial of ibrutinib plus rituximab in Waldenstrom's macroglobulinemia. N Engl J Med2018; 378(25): 2399–2410.
6.
StephensDMByrdJC. How we manage ibrutinib intolerance and complications in patients with chronic lymphocytic leukemia?Blood2019; 133: 1298–1307.
ZamoranoJLLancellottiPRodriguez MunozD, et al.2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: the Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur Heart J2016; 37(36): 2768–2801.
9.
AlessandraMGiorgiaSGiovanniF, et al.Drug-related cardiotoxicity for the treatment of haematological malignancies in elderly. Curr Pharm Des2010; 16(26): 2872–2879.
10.
Garcia-AlvarezAGarcia-AlbenizXEsteveJ, et al.Cardiotoxicity of tyrosine-kinase-targeting drugs. Cardiovasc Hematol Agents Med Chem2010; 8(1): 11–21.
11.
LeDLCaoHYangL-X. Cardiotoxicity of molecular-targeted drug therapy. Anticancer Res2014; 34(7): 3243–3249.
12.
HallekMFischerKFingerle-RowsonG, et al.Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet2010; 376(9747): 1164–1174.
13.
HallekMChesonBDCatovskyD, et al.iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood2018; 131(25): 2745–2760.
14.
BarrPMRobakTOwenC, et al.Sustained efficacy and detailed clinical follow-up of first-line ibrutinib treatment in older patients with chronic lymphocytic leukemia: extended phase 3 results from RESONATE-2. Haematologica2018; 103(9): 1502–1510.
15.
BarrientosJCO'BrienSBrownJR, et al.Improvement in parameters of hematologic and immunologic function and patient well-being in the Phase III RESONATE study of ibrutinib versus ofatumumab in patients with previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma. Clin Lymph Myelom Leuk2018; 18(12): 803–813 e7.
16.
BrownJRHillmenPO'BrienS, et al.Extended follow-up and impact of high-risk prognostic factors from the phase 3 RESONATE study in patients with previously treated CLL/SLL. Leukemia2018; 32(1): 83–91.
17.
LentzRFeinglassJMaS, et al.Risk factors for the development of atrial fibrillation on ibrutinib treatment. Leuk Lymph2019, pp. 1–7.
18.
WallaceNWongECooperD, et al.A case of new-onset cardiomyopathy and ventricular tachycardia in a patient receiving ibrutinib for relapsed mantle cell lymphoma. Clin Case Rep2016; 4(12): 1120–1121.
19.
KyiHHZayedYAl HadidiS. Ibrutinib-induced cardiomyopathy. J Community Hosp Intern Med Perspect2019; 9(1): 50–52.
20.
McMullenJRBoeyEJHOoiJYY, et al.Ibrutinib increases the risk of atrial fibrillation, potentially through inhibition of cardiac PI3K-Akt signaling. Blood2014; 124(25): 3829–3830.
21.
McMullenJRAmirahmadiFWoodcockEA, et al.Protective effects of exercise and phosphoinositide 3-kinase (p110α) signaling in dilated and hypertrophic cardiomyopathy. Proc Natl Acad Sci USA2007; 104(2): 612–617.
22.
WeeksKLGaoXDuXJ, et al.Phosphoinositide 3-kinase p110α is a master regulator of exercise-induced cardioprotection and PI3K gene therapy rescues cardiac dysfunction. Circ Heart Fail2012; 5(4): 523–534.
23.
MatoARNabhanCThompsonMC, et al.Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis. Haematologica2018; 103(5): 874–879.
